Long intergenic non-protein coding RNA 2096 (LINC02096)

Long intergenic non-protein coding RNA 2096 (LINC02096) is a member of the long intergenic non-coding RNA (lincRNA) family, a subclass of long non-coding RNAs that are transcribed from genomic regions not overlapping known protein-coding genes[1][3][5]. LINC02096 is primarily characterized by its regulatory roles in gene expression, including chromatin remodeling and transcriptional modulation. Recent studies highlight its involvement in mediating resistance to cancer immunotherapy, notably by upregulating immune checkpoint markers such as PD-L1 and IDO-1 in tumor-associated macrophages, which can promote tumor immune evasion and therapy resistance[4]. Its precise molecular function and disease spectrum can be context-dependent, reflecting the emerging and diverse biological roles ascribed to lincRNAs[1][4][7]. No approved drugs directly target LINC02096, but its expression may impact the efficacy of immunotherapy regimens, making it a potential biomarker and putative novel target in oncology.

Other names

LINC02096

Mediates immunotherapy resistance by increasing tumor cell expression of immune checkpoint markers such as PD-L1 and IDO-1